MRK vs PFE: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.

MRK

Merck & Co., Inc. · Healthcare

$113.87

-12.1% upside to fair value

Grade D High Quality

PFE

Pfizer Inc. · Healthcare

$25.22

+2.8% upside to fair value

Grade B

QuantHub Verdict

PFE has more upside to fair value (+2.8%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →

Valuation & Fundamentals

Metric	MRK	PFE
Current Price	$113.87	$25.22
Fair Value Estimate	$100.14	$25.92
Upside to Fair Value	-12.1%	+2.8%
Market Cap	$281.2B	$143.7B
Forward P/E	32.0x	19.2x
EV / EBITDA	17.3x	12.3x
Price / Sales	4.3x	2.3x
Price / FCF	19.9x	15.2x
Revenue Growth YoY	+4.3%	+5.4%
Gross Margin	75.9%	69.3%
Operating Margin	27.6%	23.4%
Return on Equity	17.9%	8.4%
Dividend Yield	0%	0%
FCF Yield	5.02%	6.6%
Analyst Consensus	Hold	Hold

Investment Thesis

MRK — Merck & Co., Inc.

Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…

PFE — Pfizer Inc.

Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…

Accumulation Zones

Metric	MRK	PFE
Zone Low	$75.11	$19.44
Zone High	$85.12	$22.03
In Buy Zone?	No	No

← MRK Research PFE Research → All Research